PHVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pharvaris NV (PHVS) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the stock has positive catalysts such as strong analyst ratings and promising drug developments, the lack of significant financial growth, insider selling activity, and limited trading signals suggest waiting for a more favorable entry point.
The technical indicators show a bullish trend with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). RSI is neutral at 61.967, and the stock is trading near its resistance level of R1: 29.091. However, the stock's trend analysis indicates a higher probability of short-term declines (-3.95% in the next week).
Analysts have consistently raised price targets, with the latest target at $52, citing strong efficacy and market potential for deucrictibant.
The company's drug pipeline shows promise, with key milestones expected in Q3
Bullish sentiment from analysts, with multiple Outperform ratings.
Insider selling by the CEO, reducing direct holdings, which may indicate a lack of confidence in short-term price growth.
The company reported a significant net loss of €176 million in 2025, with no revenue growth.
Stock trend analysis suggests potential short-term declines.
Pharvaris reported a net loss of €176 million in 2025/Q4 with no revenue growth. Despite this, cash reserves increased to €292 million, providing financial stability. However, EPS remains negative at -0.72, reflecting ongoing losses.
Analysts are bullish on Pharvaris, with multiple Outperform ratings and price targets ranging from $42 to $52. They highlight the potential of deucrictibant to dominate the hereditary angioedema market due to its efficacy, safety, and oral convenience.
